The purpose of this clinical research study is to assess the safety, reactogenicity and immunogenicity of an investigational Epstein-Barr Virus (Mono) vaccine in 10 to 21-year old healthy Adolescents and Adults.

Epstein-Barr Virus is a very common virus that is spread from person to person by close contact beginning in childhood. By age 24, about 90% of people will have already had an EBV infection. EBV is also the main cause of an illness called infectious mononucleosis (IM), which occurs more often when you are first infected as a teenager or young adult. Infectious mononucleosis, sometimes called “mono”, causes symptoms such as fever, tiredness, sore throat, and swollen lymph nodes. Some symptoms, like tiredness, can last for months in some people. Most people have no symptoms with EBV infection, which can remain in the body for life and not cause any symptoms.

This study will test a new investigational vaccine which is being developed for prevention of IM. A safe and effective vaccine may potentially prevent IM and protect against EBV infection. There is currently no approved vaccine to prevent IM and EBV infection.

To qualify for the study, you must be:

• Aged 10 to 21 years on the day of inclusion
• Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and judgment of the investigator.
• Other criteria may apply*

*There are multiple studies available to participate in and each may require different criteria to be approved as a participant.

To learn more about this trial and to find out if you qualify, please call 402.934.0044 or complete the form on our Contact page.